Risk Evaluation And Mitigation

An updated analysis published in The Cochrane Database of Systematic Reviews has fueled debate about the effectiveness of masks to prevent the spread of COVID-19.

The FDA can require a safety program called a Risk Evaluation and Mitigation Strategy, or REMS, for a medication with serious safety concerns to ensure the benefits outweigh the risks. An REMS is designed to reinforce behaviors and actions that support safe use of that medication to mitigate a specific risk.

N-terminal pro-B-type natriuretic peptide levels before noncardiac surgery was strongly linked to myocardial injury and vascular death within 30 days after the procedure and may improve cardiac risk prediction along with the Revised Cardiac Risk Index, according to a study published in the Annals of Internal Medicine.